Free Trial

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific logo
$107.42 +0.89 (+0.84%)
As of 03:05 PM Eastern

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
24

Based on 24 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Buy." Out of the 24 analysts, 21 have given a buy rating, and 3 have given a strong buy rating for BSX.

Consensus Price Target

$116.09
8.07% Upside
According to the 24 analysts' twelve-month price targets for Boston Scientific, the average price target is $116.09. The highest price target for BSX is $130.00, while the lowest price target for BSX is $100.00. The average price target represents a forecasted upside of 8.07% from the current price of $107.42.
Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

Sign Up

BSX Analyst Ratings Over Time

TypeCurrent Forecast
6/30/24 to 6/30/25
1 Month Ago
5/31/24 to 5/31/25
3 Months Ago
4/1/24 to 4/1/25
1 Year Ago
7/1/23 to 6/30/24
Strong Buy
3 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
21 Buy rating(s)
20 Buy rating(s)
21 Buy rating(s)
19 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$116.09$116.00$108.91$76.70
Forecasted Upside8.07% Upside10.39% Upside7.62% Upside-0.41% Downside
Consensus Rating
Buy
Buy
Buy
Moderate Buy

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Boston Scientific Stock vs. The Competition

TypeBoston ScientificMedical CompaniesS&P 500
Consensus Rating Score
3.13
2.81
2.53
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside8.67% Upside8,559.07% Upside12.42% Upside
News Sentiment Rating
Positive News

See Recent BSX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/16/2025Leerink Partnrs
1 of 5 stars
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025Leerink Partners
1 of 5 stars
Mike Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$118.00+18.47%
5/28/2025Needham & Company LLC
2 of 5 stars
M. Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00+9.31%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$119.00 ➝ $125.00+19.59%
5/16/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Wood
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$120.00 ➝ $125.00+18.58%
5/8/2025Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
H. Engel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/25/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$118.00 ➝ $125.00+23.60%
4/24/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$116.00 ➝ $120.00+18.22%
4/24/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Richard Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$113.00 ➝ $117.00+16.33%
4/24/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$110.00 ➝ $112.00+13.12%
4/24/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$115.00 ➝ $120.00+21.20%
4/23/2025BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Marie Thibault
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$124.00+25.24%
2/18/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$130.00+24.98%
2/7/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Danielle Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$105.00 ➝ $130.00+23.64%
2/6/2025Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jayson Bedford
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetStrong-Buy ➝ Strong-Buy$119.00 ➝ $122.00+15.87%
2/6/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rick Wise
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$100.00 ➝ $115.00+9.25%
2/6/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Larry Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$100.00 ➝ $118.00+12.51%
2/3/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt O'Brien
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$95.00 ➝ $115.00+11.65%
1/10/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$108.00+12.64%
12/16/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$100.00 ➝ $110.00+21.21%
12/12/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$100.00 ➝ $110.00+21.11%
12/9/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$98.00 ➝ $101.00+12.92%
10/24/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$92.00 ➝ $100.00+16.41%
10/24/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$100.00 ➝ $110.00+25.79%
10/22/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$90.00 ➝ $100.00+13.39%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.00+20.05%
2/1/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$58.00 ➝ $68.00+5.44%
6/30/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingInitiates
6/30/2023CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$64.00+20.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:23 PM ET.


Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 27, 2025. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • The current stock price is around $102.88, which may present a buying opportunity for investors looking for value in the medical device sector.
  • Boston Scientific Co. has a strong presence in the medical device market, particularly in interventional specialties, which is a growing field due to increasing healthcare demands.
  • Recent insider trading activity indicates confidence in the company's future, with executives holding significant shares even after selling portions of their holdings.
  • The company has reported substantial sales of its stock by insiders, totaling over $42 million in the last quarter, suggesting active management engagement and potential for future growth.
  • Boston Scientific Co. operates through two key segments, MedSurg and Cardiovascular, allowing for diversified revenue streams and resilience against market fluctuations.

Boston Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • Insider sales have resulted in a decrease in ownership percentages, with some executives reducing their positions by over 24%, which may raise concerns about their confidence in the company's short-term performance.
  • Despite the company's strong market position, the stock has experienced fluctuations, and recent sales by executives could indicate potential volatility ahead.
  • Only 0.50% of the stock is currently owned by company insiders, which may suggest a lack of alignment between management and shareholder interests.
  • The medical device industry faces regulatory challenges and competition, which could impact Boston Scientific Co.'s market share and profitability.
  • Recent insider trading activity, while indicating engagement, also reflects a trend of executives liquidating shares, which could signal caution for potential investors.

BSX Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $116.09, with a high forecast of $130.00 and a low forecast of $100.00.

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 21 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BSX shares.

According to analysts, Boston Scientific's stock has a predicted upside of 8.07% based on their 12-month stock forecasts.

Over the previous 90 days, Boston Scientific's stock had 3 upgrades by analysts.

Analysts like Boston Scientific more than other "medical" companies. The consensus rating for Boston Scientific is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BSX compares to other companies.


This page (NYSE:BSX) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners